Lasmiditan for the treatment of migraine

  title={Lasmiditan for the treatment of migraine},
  author={Matilde Capi and Fernando de Andr{\'e}s and Luana Lionetto and Giovanna Gentile and Fabiola Cipolla and Andrea Negro and Marina Borro and Paolo Martelletti and Martina Curto},
  journal={Expert Opinion on Investigational Drugs},
  pages={227 - 234}
ABSTRACT Introduction: Migraine is one of the most common diseases in the world, with high economical and subjective burden. Migraine acute therapy is nowadays based on specific and non-specific drugs but up to 40% of episodic migraineurs still have unmet treatment needs and over 35% do not benefit from triptans administration. Serotonin-1F receptors have been identified in trigeminal system and became an ideal target for anti-migraine drug development as potential trigeminal neural inhibitors… 

Profiling lasmiditan as a treatment option for migraine

The most recent phase III trials have demonstrated the efficacy of lasmiditan for acute migraine treatment, even if compared only with placebo, and the low rate of cardiovascular side effects with lasmIDitan might offer a potential therapeutic option for migraine patients with cardiovascular disorders.

Lasmiditan: an additional therapeutic option for the acute treatment of migraine

Lasmiditan can be safely prescribed in patients who have failed non-steroid anti-inflammatory drugs or triptans or with cardiovascular risk factors, and has a positive effect on migraine-related disability.

The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine

The efficacy of lasmiditan proves that vasoconstriction is not essential for acute migraine therapy and thereby points, in addition to a well-established trigeminal contribution, to central neuronal mechanisms in migraine pathophysiology.

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice

Research to date suggests lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment option in patients refractory to current acute migraine medications or who have cardiovascular risk factors.

The therapeutic impact of new migraine discoveries.

Clinical and preclinical studies are needed to untangle the pathophysiology of migraine in order to develop new and migraine-specific therapies, and current therapeutic approaches are not suitable for all migraine patients.

Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential

Lasmiditan is considered to be the first member of a new drug category, the neurally acting anti-migraine agent (NAAMA), and Phase II and III trials had shown superiority compared to placebo and absence of typical triptan-associated adverse events (AEs).

Acute treatment of migraine: quo vadis?

A new call for action is required in order to reduce the personal, working, and pharmaco-economic impact and the public health expenditure caused by this pathology, that could be appropriately defined as a social disease from now on.

Targeted 5-HT1F Therapies for Migraine

Although ongoing phase III clinical trials are needed to confirm its efficacy and safety, lasmiditan might offer an alternative to treat acute migraine with no associated cardiovascular risk.

Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies

This article reviews current preventive treatments and their shortcomings and the road that, through the understanding of calcitonin gene-related peptide (CGRP) role in migraine pathophysiology, carried to the approval of the 3 first-in-class monoclonal antibodies (mAbs) acting on the CGRP pathway.



Emerging drugs for migraine treatment

The most convincing results appear those obtained with mAbs against CGRP, particularly in migraine preventative treatment, given the absence of serious adverse events, and the good response in terms of pain relief.

The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine

Lasmiditan tablets in doses of 50–400 mg show significant headache relief after 2 hours compared with placebo and improved accompanying symptoms, which is reflected by its dose-dependent adverse event profile chiefly including dizziness, vertigo, paresthesia and fatigue.

Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

The novel pharmacological possibilities that influence the peripheral and central sensitization involved in the disease are reviewed, based on a PubMed search, to overcome the therapeutic insufficiency.

Anti-CGRP monoclonal antibodies in migraine: current perspectives

Although not all migraineurs respond to this treatment, and longer administration periods will be needed to assess long-term effects, the results so far obtained are extraordinarily promising and probably represent a turning point for prevention similar to that represented by triptans for abortive treatment in migraine.

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan

  • P. Rizzoli
  • Biology, Medicine
    Neuropsychiatric disease and treatment
  • 2014
Study results support an emerging central neuronal mechanism of migraine pathophysiology and trace the history and use of 5-HT1F receptor agonists, now referred to as neurally acting anti-migraine agents in migraine management.

CGRP receptor antagonists: an expanding drug class for acute migraine?

Gepants, a CGRP antagonist class, might offer a new non-vasoconstrictive approach in the acute treatment of migraine, corresponding to the best published results for oral triptans.

Oral sumatriptan for acute migraine.

Oral sumatriptan has been shown to be an effective drug for the treatment of a single acute attack of migraine and is well tolerated, though minor adverse events were not uncommon in the included trials.

Drug safety in acute migraine treatment

The frequent use of analgesics, ergot alkaloids and triptans may result in the development of medication overuse headache (MOH), and there is a need for pathomechanism-based drugs, and for the future achievement of personalized medicine.

Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial

The non-vascular, neural mechanism of action of lasmiditan may offer an alternative means to treat migraine especially in patients who have contra-indications for agents with vasoconstrictor activity.

The therapeutic armamentarium in migraine is quite elderly

  • P. Martelletti
  • Medicine
    Expert opinion on drug metabolism & toxicology
  • 2015
Global Burden of Disease 2010 study considers migraine as one of the most important noncommunicable diseases in the world, classifying it third in terms of global prevalence (14.70%): it sums up the